Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Capsugel
Synlogic |
| gptkbp:ceo |
gptkb:Marc_Funk
|
| gptkbp:certification |
ISO certified
|
| gptkbp:employees |
Over 15,000
|
| gptkbp:focus_area |
gptkb:Sustainability_initiatives
gptkb:supply_chain_management Regenerative medicine Quality control Digital transformation Regulatory compliance Vaccines Gene editing Cell culture Regulatory support Lyophilization Product lifecycle management Technology transfer Antibody production Process optimization Microbial fermentation Analytical services Process development Custom development Clinical trial material production Fill and finish services Patient-centric solutions Commercial manufacturing Bioconjugates Cell and gene therapy manufacturing Drug product development Innovation in biomanufacturing |
| gptkbp:founded |
1897
|
| gptkbp:founder |
Alfred Ammon
|
| gptkbp:global_presence |
gptkb:Yes
|
| gptkbp:headcount |
Approximately 15,000
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lonza Biologics
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:location |
Multiple global locations
|
| gptkbp:market_cap |
Publicly traded
|
| gptkbp:parent_company |
gptkb:Lonza_Group
|
| gptkbp:partnerships |
Various pharmaceutical companies
|
| gptkbp:products |
Biologics
Small molecules Cell and gene therapies |
| gptkbp:research_and_development |
Significant investment in R& D
|
| gptkbp:research_focus |
Biopharmaceuticals
|
| gptkbp:revenue |
Over $5 billion
|
| gptkbp:services |
Contract manufacturing
Development services |
| gptkbp:subsidiaries |
Lonza Houston
Lonza Biologics UK Lonza Walkersville Lonza Biologics Switzerland |
| gptkbp:website |
www.lonza.com
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:bfsLayer |
6
|